Pacira | PCRX - Current Liabilities


Pacira reported $108.79M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Astellas Pharma JPY 1.22T 106.19B Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
Teva Pharmaceutical Industries USD 13.53B 76M Mar/2026
Xeris Pharmaceuticals USD 118.59M 9.02M Mar/2026
Xoma USD 28.3M 6.81M Sep/2025
Zoetis USD 2.05B 182M Mar/2026